BDTX-1535 FOR RECURRENT HIGH-GRADE GLIOMA
  • January 8, 2024
The Ivy Brain Tumor Center is conducting a Phase 0/1 clinical trial to evaluate BDTX-1535, an experimental drug intended to block a key growth signal in patients with recurrent high-grade glioma, driven by EGFR (Epidermal Growth Factor Receptor) genetic aberrations.
Learn More
ONC201 IN NEWLY DIAGNOSED H3 K27M-MUTANT DIFFUSE GLIOMA
  • August 4, 2023
The Ivy Brain Tumor Center at Barrow Neurological Institute, a nonprofit translational research program, is conducting a Phase 3 study to evaluate ONC201 in patients with newly diagnosed H3 K27M-mutant diffuse glioma.
Learn More
PAMIPARIB IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
  • February 28, 2022
A Phase 0/2 study of pamiparib (a PARP inhibitor) in newly diagnosed and recurrent glioblastoma patients to evaluate brain penetration and tumor effects.
Learn More
ABEMACICLIB PLUS LY3214996 FOR RECURRENT GLIOBLASTOMA
  • February 6, 2022
A Phase 0 clinical trial combining Abemaciclib (CDK4/6 inhibitor) and LY3214996 (ERK inhibitor) in recurrent glioblastoma patients scheduled for resection to evaluate central nervous system (CNS) penetration.
Learn More
DSC-MRI FOR RECURRENT GLIOBLASTOMA
  • February 5, 2021
A Phase 2 trial that studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to Bevacizumab in patients with glioblastoma that has come back. DSC-MRI may help evaluate changes in the blood vessels within the cancer to determine a patient's response to treatment.
Learn More
INFIGRATINIB FOR RECURRENT HIGH-GRADE GLIOMA
  • February 4, 2021
A Phase 0 study of infigratinib in recurrent high-grade glioma patients with an FGFR gene fusion scheduled for resection to evaluate central nervous system (CNS) penetration with PK triggered expansion cohort.
Learn More